Beta Bionics, Inc. BBNX
We take great care to ensure that the data presented and summarized in this overview for Beta Bionics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in BBNX
Top Purchases
Top Sells
About BBNX
Insider Transactions at BBNX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 03
2025
|
Stephen Feider Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
4,982
-5.18%
|
$104,622
$21.9 P/Share
|
|
Oct 03
2025
|
Stephen Feider Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,982
+9.23%
|
$24,910
$5.1 P/Share
|
|
Oct 01
2025
|
Stephen Feider Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
15,018
-12.74%
|
$300,360
$20.92 P/Share
|
|
Oct 01
2025
|
Stephen Feider Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,018
+20.27%
|
$75,090
$5.1 P/Share
|
|
Sep 08
2025
|
Stephen Feider Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
9,900
-18.35%
|
$207,900
$21.13 P/Share
|
|
Sep 08
2025
|
Stephen Feider Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,900
+15.51%
|
$49,500
$5.1 P/Share
|
|
Sep 05
2025
|
Stephen Feider Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
100
-0.23%
|
$2,100
$21.0 P/Share
|
|
Sep 05
2025
|
Stephen Feider Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
100
+0.23%
|
$500
$5.1 P/Share
|
|
Sep 05
2025
|
Mark Hopman Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
11,411
-26.77%
|
$228,220
$20.56 P/Share
|
|
Sep 05
2025
|
Mark Hopman Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,411
+21.12%
|
$57,055
$5.1 P/Share
|
|
Sep 04
2025
|
Mark Hopman Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
6,818
-17.93%
|
$129,542
$19.97 P/Share
|
|
Sep 04
2025
|
Mark Hopman Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,749
+5.81%
|
$23,745
$5.1 P/Share
|
|
Sep 02
2025
|
Stephen Feider Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,462
-3.21%
|
$26,316
$18.86 P/Share
|
|
Sep 02
2025
|
Mark Hopman Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
848
-2.48%
|
$15,264
$18.86 P/Share
|
|
Sep 02
2025
|
Mike Mensinger Chief Product Officer |
SELL
Open market or private sale
|
Direct |
1,089
-1.17%
|
$19,602
$18.86 P/Share
|
|
Sep 02
2025
|
Steven Jon Russell Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,015
-1.41%
|
$18,270
$18.86 P/Share
|
|
Sep 02
2025
|
Sean Saint President & CEO |
SELL
Open market or private sale
|
Direct |
3,359
-3.21%
|
$60,462
$18.86 P/Share
|
|
Aug 22
2025
|
Stephen Feider Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
4,413
-8.84%
|
$75,021
$17.01 P/Share
|
|
Aug 22
2025
|
Stephen Feider Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,413
+8.12%
|
$22,065
$5.1 P/Share
|
|
Aug 19
2025
|
Stephen Feider Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,587
-10.94%
|
$94,979
$17.03 P/Share
|
Last 12 Months Summary
Buy / Acquisition
4.36M
Shares
From
18
Insiders
| Grant, award, or other acquisition | 329K shares |
|---|---|
| Conversion of derivative security | 2.92M shares |
| Open market or private purchase | 1.03M shares |
| Exercise of in-the-money or at-the-money derivatives securities | 10.6K shares |
| Exercise of conversion of derivative security | 72.3K shares |
Sell / Disposition
90.1K
Shares
From
5
Insiders
| Open market or private sale | 90.1K shares |
|---|